RT Journal Article
SR Electronic
T1 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.01.20029074
DO 10.1101/2020.03.01.20029074
A1 Li Tan
A1 Qi Wang
A1 Duanyang Zhang
A1 Jinya Ding
A1 Qianchuan Huang
A1 Yi-Quan Tang
A1 Qiongshu Wang
A1 Hongming Miao
YR 2020
UL http://medrxiv.org/content/early/2020/03/03/2020.03.01.20029074.abstract
AB Background Coronavirus disease-2019 (COVID-19) is a rapidly escalating epidemic caused by SARS-CoV-2. Identification of a simple and effective indicator to assess disease severity and prognosis is urgently needed.Methods Dynamic changes of blood lymphocyte percentage (LYM%) in 15 death cases, 15 severe cases as well as 40 moderate cases of COVID-19 patients were retrospectively analyzed. A Time-LYM% model (TLM) was established according to the descriptive studies and was validated in 92 hospitalized cases.Results Results from death and severe cases showed that LYM% in blood tests were inversely associated with the severity and prognosis of COVID-19. LYM% in moderate type of patients with COVID-19 remained higher than 20% 10-12 days after symptom onset. In contrast, LYM% was lower than 20% in severe cases. However, LYM% in severe cases was higher than 5% 17-19 days after the onset of the disease, while it fell below 5% in death cases. Accordingly, we established a Time-LYM% model (TLM), which was validated as an independent criterion of disease classification in another 92 hospitalized patients with COVID-19.Conclusion Lymphopenia can be used as an indicator of disease severity and prognosis of COVID-19 patients. TLM is worth of application in the clinical practice.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/VFunding StatementThis work was supported by the award numbers cstc2017jcyjBX0071 (H.M.) from the Foundation and Frontier Research Project of Chongqing and T04010019 (H.M.) from Chongqing youth top talent project.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data that support the findings of this study are available within the article and its Supplementary file or from the corresponding author upon reasonable request. The supplementary file includes 3 Tables.